
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Ober Gabelhorn glacier reveals remains of man missing for over three decades - 2
Discovery of massive spider's web in Greece reveals unexpected behavior - 3
The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs - 4
What's your biological age? Experts explain the benefits and risks of at-home tests - 5
Get away from the Tedious Drudgery: Go into Business Today!
Virtual reality opens doors for older people to build closer connections in real life
Moon-bound Artemis II astronauts enjoy a relaxed day in space
ISS astronauts spy airglow and dwarf galaxy | Space photo of the day for Jan. 13, 2026
Smooth countdown continues for Artemis II moon mission
Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
Manual for Instructive Application for Youngsters
Dozens of hidden star streams found in the outskirts of our Milky Way galaxy
Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
Surprise! Saturn's huge moon Titan may not have a buried ocean after all













